Taysha Gene Therapies, Inc.(TSHA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,855 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
TSHA Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Taysha Gene Therapies, Inc. (TSHA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TSHA at 4.1/100 on a 32-signal composite quality model, placing it at rank #2,855 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (1.2) and free cash flow (1.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Taysha Gene Therapies, Inc. reports net income of $-42.4M, free cash flow of $-40.9M. Top institutional holders of TSHA by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., GOLDMAN SACHS GROUP, Avoro Capital Advisors, based on the most recent SEC filings. TSHA trades on the Nasdaq exchange and files with the SEC under CIK 1806310. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TSHA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Taysha Gene Therapies, Inc. directly from SEC EDGAR. Taysha Gene Therapies, Inc.'s 13F Pro composite quality score has ranged between 4 and 40 since 2023, currently 4.1 — a declining long-term trajectory across 25 quarterly and live scoring snapshots.
Revenue
Q1 2026
$0.00
Net Income
Q1 2026
$-42.4M
Free Cash Flow
Q1 2026
$-40.9M
D/E Ratio
Q1 2026
0.23
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+17.3% YoYNet Income
-22.1% YoYOperating Income
-20.8% YoYEPS (Diluted)
+5.6% YoYTotal Assets
+114.1% YoYTotal Debt
+14.0% YoYOp. Cash Flow
-14.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $9.8M +17.3% | $8.3M -46.1% | $15.5M +517.5% | $2.5M | — | — |
| Net Income | $-109.0M -22.1% | $-89.3M +20.0% | $-111.6M +32.8% | $-166.0M +4.9% | $-174.5M | — |
| Operating Income | $-110.5M -20.8% | $-91.5M -26.3% | $-72.4M +55.4% | $-162.4M +6.2% | $-173.3M | — |
| EPS (Diluted) | $-0.34 +5.6% | $-0.36 +62.5% | $-0.96 +23.8% | $-1.26 +18.5% | $-1.55 | — |
| Total Assets | $343.3M +114.1% | $160.4M -7.2% | $172.7M +36.8% | $126.3M -41.0% | $214.0M +1426273.3% | $15.0K |
| Total Debt | $50.1M +14.0% | $43.9M +8.5% | $40.5M +6.7% | $38.0M +2.1% | $37.2M | — |
| Operating Cash Flow | $-93.1M -14.6% | $-81.2M -11.2% | $-73.0M +17.4% | $-88.4M +24.5% | $-117.0M | — |
AI Insight: TSHA Financial Trends
Equity was rebuilt via likely financing in Q2 2025, but operating losses are accelerating sharply — Q1 2026 op loss hit -$43M, the worst in the dataset.
• Operating losses deepened from -$21M in Q2 2024 to -$43M in Q1 2026, with the sharpest single-quarter deterioration in Q1 2026.
• Equity collapsed from $109M in Q2 2024 to $55M in Q1 2025, then surged to $249M in Q2 2025, suggesting a material capital raise.
• Equity has since eroded from $249M in Q2 2025 to $212M in Q1 2026 as losses continue to consume capital.
• Operating cash outflow worsened to -$41M in Q1 2026, the largest quarterly cash burn in the observed period.
⚠ At -$41M quarterly operating cash burn, the $212M equity base implies a limited runway — pace of cash consumption is critical to monitor.
⚠ Revenue dropped to $0M in Q1 2026 after reaching $5M in Q4 2025 — sustainability of any revenue stream remains unproven.
⚠ Total debt edged up to $51M in Q3 2025 and remains near $49–50M — leverage trajectory warrants monitoring alongside cash burn.
AI Insight: TSHA Ratio Trends
Losses remain deep but leverage has sharply contracted since Q1 2025, suggesting improved capital structure despite no path to profitability.
• D/E peaked at 0.77 in Q1 2025 and fell to 0.23 by Q1 2026, a meaningful deleveraging over four quarters.
• ROE deteriorated sharply from -76.9% in Q2 2024 to -156.4% in Q1 2025 before partially recovering to -80.0% in Q1 2026.
• ROA of -56.5% and ROIC of -66.7% in Q1 2026 reflect continued heavy capital consumption with no revenue base visible in the data.
⚠ ROE worsened from -45.1% in Q4 2025 to -80.0% in Q1 2026 — a sharp single-quarter deterioration worth monitoring.
⚠ OpMargin and NPM are absent throughout; any revenue recognition or milestone payment could materially shift the return profile.
Get alerted when TSHA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Taysha Gene Therapies, Inc. including:
Top Institutional Holders of TSHA
RA CAPITAL MANAGEMENT, L.P.
$105.3M23,555,648 shGOLDMAN SACHS GROUP INC
$100.0M22,369,645 shAvoro Capital Advisors LLC
$97.0M21,700,000 shBlackRock, Inc.
$82.1M18,365,608 shVestal Point Capital, LP
$80.5M18,000,000 shMORGAN STANLEY
$80.3M17,965,371 shFMR LLC
$64.0M14,321,255 shRTW INVESTMENTS, LP
$61.2M13,680,248 shSTATE STREET CORP
$50.1M11,209,078 shVANGUARD CAPITAL MANAGEMENT LLC
$45.7M10,231,502 sh
| Fund | Value | Shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $105.3M | 23,555,648 |
| GOLDMAN SACHS GROUP INC | $100.0M | 22,369,645 |
| Avoro Capital Advisors LLC | $97.0M | 21,700,000 |
| BlackRock, Inc. | $82.1M | 18,365,608 |
| Vestal Point Capital, LP | $80.5M | 18,000,000 |
| MORGAN STANLEY | $80.3M | 17,965,371 |
| FMR LLC | $64.0M | 14,321,255 |
| RTW INVESTMENTS, LP | $61.2M | 13,680,248 |
| STATE STREET CORP | $50.1M | 11,209,078 |
| VANGUARD CAPITAL MANAGEMENT LLC | $45.7M | 10,231,502 |
More Healthcare Companies
View all Healthcare →Put TSHA on your watchlist
Track score changes the day Taysha Gene Therapies, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TSHA a good stock to buy?
13F Pro's AI-powered analysis of Taysha Gene Therapies, Inc. (TSHA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TSHA are available on the TSHA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own TSHA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TSHA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Taysha Gene Therapies, Inc.'s investment landscape.